HC Wainwright analysts have set the price target for MacroGenics (NASDAQ: MGNX) increased from $10.00 to $11.00 on Tuesday, as reported by The Fly. Before this adjustment, the price target was set at $10.00. The company’s target price, set by HC Wainwright, is 177.78% higher than its current price. This means that it has the potential to go up by that amount.

In addition to these two, there have been quite a few other industry professionals who have given their opinions regarding the stock. Barclays stated in a research note released on August 15 that they would be decreasing their price target for MacroGenics shares to $8.00. The note was published on the same day. SVB Leerink gave MacroGenics shares an “outperform” rating in a research report published on Tuesday, August 9. The report also stated that the brokerage firm’s target price for the company’s stock decreased from $15.00 to $12.00. In addition, the company gave the stock a “buy” rating and recommended that investors purchase it. In a research note published on Tuesday, July 12, JMP Securities lowered their target price on MacroGenics shares from $24.00 to $20.00 and gave the stock a “market outperform” rating in a research note. In addition, JMP Securities rated the stock as “market outperform,” suggesting that it will outperform the market. MacroGenics’ rating at BMO Capital Markets was changed from “outperform” to “market perform” in a research note issued on July 11 and published that same day. In addition to this, the company dropped its target price for the company down to $4.00 from $31.00. On Wednesday, October 12, a research report on MacroGenics shares was published on StockNews.com, marking the beginning of that website’s company shares coverage. They advised investors to “hold” onto the stock rather than sell it. A total of five investment analysts think that the stock ought to be purchased, while only four are of the opinion that it ought to be held. According to the information provided by Bloomberg, the company has been given a “Moderate Buy” recommendation on average, and the price target has been established at $12.44.
On Tuesday, the cost of purchasing a share of MGNX stock was set at $3.96 when trading began. The company’s beta value is 1.91, and its price-to-earnings ratio stands at -1.11. The company currently has a market capitalization of 244.38 million dollars. The moving average of the company’s stock price over the past 50 days is $3.86, and the moving average over the last 200 days is $4.45. During the previous twelve months, the cost of a bottle of MacroGenics fluctuated between $2.13 and $22.68.

MacroGenics (NASDAQ: MGNX) released the most recent quarterly results report that it had been working on Monday, August 8. The biopharmaceutical company’s earnings per share for the quarter came in at $0.67, which was $0.30 more than the consensus estimate of $0.97. The revenue for the quarter came in at $26.01 million, which was significantly higher than the $14.59 million analysts had anticipated for the quarter. MacroGenics had a return on equity of 102.68%, and the company had a negative net margin of 326.76% of the time. MacroGenics had a return on equity of 102.68%. According to the projections of research analysts, MacroGenics’ current fiscal year is expected to end with a loss of 2.24 cents per share. This information is derived from research conducted by analysts.

Several hedge funds and institutional investors participated in recent company stock transactions by buying and selling shares. The Vanguard Group Inc. increased the amount of MacroGenics stock held by 2.2% during the year’s first quarter. The Vanguard Group Inc. now holds 4,032,239 shares of the biopharmaceutical company’s stock, which has a value of $35,524,000. This resulted from purchasing 86,061 additional shares during the most recent fiscal quarter. The value of State Street Corporation’s holdings in MacroGenics increased by 21.7% during the first three months of 2018. State Street Corp is now the owner of 3,544,724 shares of the company’s stock after purchasing an additional 632,054 shares during the preceding quarter. This resulted in a market valuation of $31,229,000 for State Street Corp. During the second quarter; Millennium Management LLC achieved a 68.0% increase in the ownership proportion of MacroGenics stock that it held. After purchasing an additional 1,055,927 shares during the most recent period, Millennium Management LLC is now the owner of 2,609,562 shares of the biopharmaceutical company’s stock. The value of the stock holdings held by Millennium Management LLC as of the most recent market close is $7,698,000. During the second quarter, Assenagon Asset Management S.A. completed a 43.6% increase in the amount of MacroGenics stock held in its portfolio. Assenagon Asset Management S.A. now has a total of 1,800,663 shares of the biopharmaceutical company’s stock after purchasing an additional 547,004 shares during the period in question. The stock is currently valued at $5,312,000. Lastly, but certainly not least, during the second quarter, Renaissance Technologies LLC increased the amount of MacroGenics stock owned by 144.3%. This is not to be considered the least significant accomplishment. After purchasing an additional 845,211 shares during the most recent period, Renaissance Technologies LLC now owns 1,430,923 shares of the biopharmaceutical company’s stock, valued at $4,221,000. These shares were acquired during the most recent period.

MacroGenics, Inc. is a biopharmaceutical company based in the United States that focuses on developing, developing, and commercializing antibody-based therapies for cancer treatment. The medication the company makes, known as MARGENZA, has been approved by the FDA (margetuximab-cake). It is a ligand that blocks the human epidermal growth factor receptor two from doing its job (HER2). It is designed to treat adult patients who have metastatic HER2-positive breast cancer and received two or more prior anti-HER2 regimens in conjunction with chemotherapy. It is also intended for patients who have received two or more prior anti-HER2 regimens in combination with other cancer treatments. In addition, the patient must have already been through at least one round of chemotherapy.

The post MacroGenics PT (NASDAQ:MGNX) Increased to $11.00 appeared first on Best Stocks.